image

REPORT SCOPE & OVERVIEW

In 2022, The Multiple Myeloma Market size amounted to USD 21748.15 Million & is estimated to reach USD 47646 Million by 2030 and increase at a compound annual growth rate of 10.3% between 2023 and 2030.

The multiple myeloma market refers to the economic and healthcare landscape surrounding the diagnosis, treatment, and management of multiple myeloma, which is a type of cancer that affects plasma cells in the bone marrow. Plasma cells are a crucial component of the immune system, and when they become cancerous and start to multiply uncontrollably, it leads to the development of multiple myeloma. Diagnosis and Testing involves the development and availability of diagnostic tools and tests that help in identifying multiple myeloma, such as blood tests, bone marrow biopsies, imaging studies (like X-rays and MRIs), and genetic testing. Treatment Options The market includes various treatment approaches, including chemotherapy, targeted therapies, immunotherapy, stem cell transplantation, and more recently, CAR-T cell therapy. Pharmaceutical companies develop and market these treatments, and healthcare providers choose the most suitable options for their patients based on factors like disease stage, patient's health, and overall treatment goals.

Multiple Myeloma Market Revenue Analysis

Ongoing research is conducted to develop new and more effective therapies for multiple myeloma. This includes investigating novel drugs, and combination therapies, and better understanding the underlying biology of the disease. The market includes services and support for patients diagnosed with multiple myeloma. This can range from access to treatment centers, support groups, counselling, and educational resources for patients and their caregivers. Healthcare Infrastructure in the multiple myeloma market also involves the healthcare facilities, infrastructure, and expertise required to diagnose, treat, and manage the disease effectively. This includes hospitals, specialized cancer centers, medical professionals, and ancillary services. Market Size and Economics is the market's size is influenced by the number of people diagnosed with multiple myeloma, the prevalence of the disease, the cost of treatments, and the revenue generated by pharmaceutical companies that develop and market these treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and their counterparts in other countries, play a significant role in approving new treatments for multiple myeloma. The regulatory landscape affects the availability and timeline for new therapies to reach the market. Patient advocacy groups and organizations work to raise awareness about multiple myeloma, provide support to patients and their families, and advocate for research funding and policy changes. The rise in the prevalence of multiple myeloma, the rise in the number of market participants that produce multiple myeloma pharmaceuticals, and the rise in the number of product releases for multiple myeloma drugs are all driving growth in the worldwide multiple myeloma market share. Multiple myeloma is a kind of blood cancer also known as Kahler's disease. A plasma cell is a kind of white blood cell that produces antibodies that help the body fight infections. These cells multiply incorrectly in the context of multiple myeloma. They allowed an excessive amount of protein into the bones and blood. It accumulates throughout the body and harms the organs.

MARKET DYNAMICS

DRIVERS:

  • The rising number of people being diagnosed with multiple myeloma contributes to the growth of the market.

  • Advancements in Research and Development is the driver of the Multiple Myeloma Market.

Ongoing research into the biology of multiple myeloma and the development of new treatment approaches drive the market. Innovations in targeted therapies, immunotherapies, and precision medicine contribute to improved patient outcomes and attract investments in research and drug development.

RESTRAIN:

  • The cost of multiple myeloma treatments can be extremely high, especially with the introduction of novel therapies.

  • Disease and Drug Resistance The Multiple Myeloma Market is hampered by progression.

Some patients might develop resistance to certain treatments over time, leading to disease progression. This can limit the long-term effectiveness of available therapies and necessitate the development of new treatment options.

OPPORTUNITY:

  • Advances in understanding the genetic and molecular mechanisms of multiple myeloma open the door for development.

  • Immunotherapies and CAR-T Cell Therapies is the opportunity for the Multiple Myeloma Market.

Immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies, have shown promising results in treating multiple myeloma. The development and optimization of these therapies offer new avenues for treatment that harness the body's immune system to fight cancer.

CHALLENGES:

  • The cost of multiple myeloma treatment, especially newer and more advanced therapies, can be prohibitively high.

  • Complex Treatment Regimens are the challenges of the Multiple Myeloma Market.

The complexity of treatment regimens, often involving combinations of drugs and therapies, can lead to difficulties in patient adherence, potentially affecting treatment efficacy.

IMPACT OF RUSSIAN UKRAINE WAR

Russia's invasion of Ukraine in 2022 has produced a tremendous humanitarian catastrophe for Ukraine and Europe, posing significant hurdles for cancer and palliative care. Of the 14-15 million Ukrainian residents still trapped in active war zones, approximately 8.2 million had become internally displaced, largely to the West, and over 6.5 million had fled as refugees. In pre-conflict Ukraine, the overall number of new cancer patients each month was estimated to be 13,128, with 1.2% being paediatric cases. Cancer cases in the refugee population (both common and incident), assuming 7.8 million migrants in 2022. Understanding the prevalent health of the community and refugees requires a vital understanding of cancer care prior to the conflict. This understanding not only drives planning for humanitarian cancer care routes (e.g., health literacy) but also establishes expectations for the scope of cancer care in refugee host nations. In this conflict between Russia and Ukraine, the Multiple Myeloma Market is a profitable business in the range of 3 % to 4 %.

IMPACT OF ONGOING RECESSION

For all cancers, every 1.2% increase in unemployment was accompanied by a 3.1% decrease in cancer incidence (or diagnosis), an 9.1% decrease in the use of radiotherapy, and a 12.5% decline in the use of surgery. The correlation was higher in blood cancer: every 1% increase in unemployment resulted in a 7.6% decrease in blood cancer diagnosis, a 17.4% decline in the use of radiotherapy for Blood cancer treatment, and a 24.6% reduction in breast cancer surgeries. The economic downturn may also have an impact on the administration of cancer therapy beyond unemployment and fear of losing a job. There might be a group of patients who, despite not having lost or fearing losing their work. In this ongoing recession, the multiple myeloma market is less profit put 1.2-1.6%.

KEY MARKET SEGMENTS

By Type

  • Chemotherapy

  • Monoclonal Antibody

  • Protease Inhibitors

  • Others

By Disease Type

  • Smoldering Multiple Myeloma

  • Active Multiple Myeloma

By End User

  • Clinics

  • Hospitals

  • Others

Multiple Myeloma Market Segmentation Analysis

REGIONAL COVERAGE:

North America

  • US

  • Canada

  • Mexico

Europe

  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America

REGIONAL ANALYSIS

North America: The market size in North America is characterised by growing prevalence and demand for treatment, as well as an increase in illness diagnosis, which is complemented by the use of sophisticated treatments. These characteristics, together with a higher healthcare spending patient population and the existence of significant businesses with pipeline candidates and imminent releases, are responsible for the region's leading share of the worldwide market.

Asia Pacific: During the projection period, Asia Pacific is expected to have a major share of the market. The rising number of regulatory approvals of important medicines in the area, together with their extended patent expiry dates, is expected to enhance therapeutics demand. New treatment approvals such as DARZALEX (daratumumab) in important countries such as Japan, as well as the presence of a big and vast prospective patient population base in the area, are expected to fuel market expansion in Asia Pacific over the projection period.

Key players

Some major key players in Multiple Myeloma Market are Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen Inc., Bristol Myers Squibb Company, Janssen Pharmaceuticals, Inc., ONO PHARMACEUTICAL CO., LTD., CELGENE CORPORATION, Genentech, Inc., Abbie Inc. and other players.

Teva Pharmaceutical Industries Ltd-Company Financial Analysis

 ​​​​​​​

RECENT DEVELOPMENT

In 2022: Kite, a Gilead subsidiary, has formed a worldwide strategic agreement with Aecellex to collaborate on the development and commercialization of the CART-ddBCMA T-cell therapy for the treatment of relapsed or refractory multiple myeloma patients. Furthermore, the CART-ddBCMA is in Phase I clinical trials. Arcellx will pay Kite an upfront payment of USD 230 million as part of the cooperation.

In 2022: Janssen Biotech's teclistamab-cqyv, the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, has been given fast clearance by the FDA for adult patients with relapsed or refractory multiple myeloma.

Multiple Myeloma Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 21748.15 Mn
Market Size by 2030  US$ 47646 Mn
CAGR   CAGR of 10.3 % From 2023 to 2030
Base Year 2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Type (Chemotherapy, Monoclonal Antibody, Protease Inhibitors, Others)
• By Disease Type (Smoldering Multiple Myeloma, Active Multiple Myeloma)
• By End User (Clinics, Hospitals, Others)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)
Company Profiles Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen Inc., Bristol Myers Squibb Company, Janssen Pharmaceuticals, Inc., ONO PHARMACEUTICAL CO., LTD., CELGENE CORPORATION, Genentech, Inc., Abbie Inc
Key Drivers • The rising number of people being diagnosed with multiple myeloma contributes to the growth of the market.
• Advancements in Research and Development is the driver of the Multiple Myeloma Market.
Market Restraints • The cost of multiple myeloma treatments can be extremely high, especially with the introduction of novel therapies.
• Disease and Drug Resistance The Multiple Myeloma Market is hampered by progression.

 

Frequently Asked Questions

Ans. The Compound Annual Growth rate for Multiple Myeloma Market over the forecast period is 10.3%.

Ans. USD 47646 million is the projected Multiple Myeloma market size of the market by 2030.

Ans. The market is likely to be driven by new releases of improved and efficient therapies, as well as the rising desire for better treatment results for patients.

Ans. CELGENE CORPORATION (Bristol Myers Squibb Company) is the global market leader.

Ans. During the projection period, the immunomodulators sector is likely to be the market leader.

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Multiple Myeloma Market Segmentation, By Type
8.1 Chemotherapy
8.2 Monoclonal Antibody
8.3 Protease Inhibitors
8.4 Others

9. Multiple Myeloma Market Segmentation, By Disease Type
9.1 Smoldering Multiple Myeloma
9.2 Active Multiple Myeloma

10. Multiple Myeloma Market Segmentation, By End User
10.1 Clinics
10.2 Hospitals
10.3 Others

11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Multiple Myeloma Market by Country
11.2.2 North America Multiple Myeloma Market by Type
11.2.3 North America Multiple Myeloma Market by Disease Type
11.2.4 North America Multiple Myeloma Market by End User
11.2.5 USA
11.2.5.1 USA Multiple Myeloma Market by Type
11.2.5.2 USA Multiple Myeloma Market by Disease Type
11.2.5.3 USA Multiple Myeloma Market by End User
11.2.6 Canada
11.2.6.1 Canada Multiple Myeloma Market by Type
11.2.6.2 Canada Multiple Myeloma Market by Disease Type
11.2.6.3 Canada Multiple Myeloma Market by End User
11.2.7 Mexico
11.2.7.1 Mexico Multiple Myeloma Market by Type
11.2.7.2 Mexico Multiple Myeloma Market by Disease Type
11.2.7.3 Mexico Multiple Myeloma Market by End User
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Multiple Myeloma Market by Country
11.3.1.2 Eastern Europe Multiple Myeloma Market by Type
11.3.1.3 Eastern Europe Multiple Myeloma Market by Disease Type
11.3.1.4 Eastern Europe Multiple Myeloma Market by End User
11.3.1.5 Poland
11.3.1.5.1 Poland Multiple Myeloma Market by Type
11.3.1.5.2 Poland Multiple Myeloma Market by Disease Type
11.3.1.5.3 Poland Multiple Myeloma Market by End User
11.3.1.6 Romania
11.3.1.6.1 Romania Multiple Myeloma Market by Type
11.3.1.6.2 Romania Multiple Myeloma Market by Disease Type
11.3.1.6.4 Romania Multiple Myeloma Market by End User
11.3.1.7 Turkey
11.3.1.7.1 Turkey Multiple Myeloma Market by Type
11.3.1.7.2 Turkey Multiple Myeloma Market by Disease Type
11.3.1.7.3 Turkey Multiple Myeloma Market by End User
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Multiple Myeloma Market by Type
11.3.1.8.2 Rest of Eastern Europe Multiple Myeloma Market by Disease Type
11.3.1.8.3 Rest of Eastern Europe Multiple Myeloma Market by End User
11.3.2 Western Europe
11.3.2.1 Western Europe Multiple Myeloma Market by Country
11.3.2.2 Western Europe Multiple Myeloma Market by Type
11.3.2.3 Western Europe Multiple Myeloma Market by Disease Type
11.3.2.4 Western Europe Multiple Myeloma Market by End User
11.3.2.5 Germany
11.3.2.5.1 Germany Multiple Myeloma Market by Type
11.3.2.5.2 Germany Multiple Myeloma Market by Disease Type
11.3.2.5.3 Germany Multiple Myeloma Market by End User
11.3.2.6 France
11.3.2.6.1 France Multiple Myeloma Market by Type
11.3.2.6.2 France Multiple Myeloma Market by Disease Type
11.3.2.6.3 France Multiple Myeloma Market by End User
11.3.2.7 UK
11.3.2.7.1 UK Multiple Myeloma Market by Type
11.3.2.7.2 UK Multiple Myeloma Market by Disease Type
11.3.2.7.3 UK Multiple Myeloma Market by End User
11.3.2.8 Italy
11.3.2.8.1 Italy Multiple Myeloma Market by Type
11.3.2.8.2 Italy Multiple Myeloma Market by Disease Type
11.3.2.8.3 Italy Multiple Myeloma Market by End User
11.3.2.9 Spain
11.3.2.9.1 Spain Multiple Myeloma Market by Type
11.3.2.9.2 Spain Multiple Myeloma Market by Disease Type
11.3.2.9.3 Spain Multiple Myeloma Market by End User
11.3.2.10 Netherlands
11.3.2.10.1 Netherlands Multiple Myeloma Market by Type
11.3.2.10.2 Netherlands Multiple Myeloma Market by Disease Type
11.3.2.10.3 Netherlands Multiple Myeloma Market by End User
11.3.2.11 Switzerland
11.3.2.11.1 Switzerland Multiple Myeloma Market by Type
11.3.2.11.2 Switzerland Multiple Myeloma Market by Disease Type
11.3.2.11.3 Switzerland Multiple Myeloma Market by End User
11.3.2.1.12 Austria
11.3.2.12.1 Austria Multiple Myeloma Market by Type
11.3.2.12.2 Austria Multiple Myeloma Market by Disease Type
11.3.2.12.3 Austria Multiple Myeloma Market by End User
11.3.2.13 Rest of Western Europe
11.3.2.13.1 Rest of Western Europe Multiple Myeloma Market by Type
11.3.2.13.2 Rest of Western Europe Multiple Myeloma Market by Disease Type
11.3.2.13.3 Rest of Western Europe Multiple Myeloma Market by End User
11.4 Asia-Pacific
11.4.1 Asia-Pacific Multiple Myeloma Market by Country
11.4.2 Asia-Pacific Multiple Myeloma Market by Type
11.4.3 Asia-Pacific Multiple Myeloma Market by Disease Type
11.4.4 Asia-Pacific Multiple Myeloma Market by End User
11.4.5 China
11.4.5.1 China Multiple Myeloma Market by Type
11.4.5.2 China Multiple Myeloma Market by End User
11.4.5.3 China Multiple Myeloma Market by Disease Type
11.4.6 India
11.4.6.1 India Multiple Myeloma Market by Type
11.4.6.2 India Multiple Myeloma Market by Disease Type
11.4.6.3 India Multiple Myeloma Market by End User
11.4.7 japan
11.4.7.1 Japan Multiple Myeloma Market by Type
11.4.7.2 Japan Multiple Myeloma Market by Disease Type
11.4.7.3 Japan Multiple Myeloma Market by End User
11.4.8 South Korea
11.4.8.1 South Korea Multiple Myeloma Market by Type
11.4.8.2 South Korea Multiple Myeloma Market by Disease Type
11.4.8.3 South Korea Multiple Myeloma Market by End User
11.4.9 Vietnam
11.4.9.1 Vietnam Multiple Myeloma Market by Type
11.4.9.2 Vietnam Multiple Myeloma Market by Disease Type
11.4.9.3 Vietnam Multiple Myeloma Market by End User
11.4.10 Singapore
11.4.10.1 Singapore Multiple Myeloma Market by Type
11.4.10.2 Singapore Multiple Myeloma Market by Disease Type
11.4.10.3 Singapore Multiple Myeloma Market by End User
11.4.11 Australia
11.4.11.1 Australia Multiple Myeloma Market by Type
11.4.11.2 Australia Multiple Myeloma Market by Disease Type
11.4.11.3 Australia Multiple Myeloma Market by End User
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Multiple Myeloma Market by Type
11.4.12.2 Rest of Asia-Pacific Multiple Myeloma Market by Disease Type
11.4.12.3 Rest of Asia-Pacific Multiple Myeloma Market by End User
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Multiple Myeloma Market by Country
11.5.1.2 Middle East Multiple Myeloma Market by Type
11.5.1.3 Middle East Multiple Myeloma Market by Disease Type
11.5.1.4 Middle East Multiple Myeloma Market by End User
11.5.1.5 UAE
11.5.1.5.1 UAE Multiple Myeloma Market by Type
11.5.1.5.2 UAE Multiple Myeloma Market by Disease Type
11.5.1.5.3 UAE Multiple Myeloma Market by End User
11.5.1.6 Egypt
11.5.1.6.1 Egypt Multiple Myeloma Market by Type
11.5.1.6.2 Egypt Multiple Myeloma Market by Disease Type
11.5.1.6.3 Egypt Multiple Myeloma Market by End User
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Multiple Myeloma Market by Type
11.5.1.7.2 Saudi Arabia Multiple Myeloma Market by Disease Type
11.5.1.7.3 Saudi Arabia Multiple Myeloma Market by End User
11.5.1.8 Qatar
11.5.1.8.1 Qatar Multiple Myeloma Market by Type
11.5.1.8.2 Qatar Multiple Myeloma Market by Disease Type
11.5.1.8.3 Qatar Multiple Myeloma Market by End User
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Multiple Myeloma Market by Type
11.5.1.9.2 Rest of Middle East Multiple Myeloma Market by Disease Type
11.5.1.9.3 Rest of Middle East Multiple Myeloma Market by End User
11.5.2 Africa
11.5.2.1 Africa Multiple Myeloma Market by Country
11.5.2.2 Africa Multiple Myeloma Market by Type
11.5.2.3 Africa Multiple Myeloma Market by Disease Type
11.5.2.4 Africa Multiple Myeloma Market by End User
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Multiple Myeloma Market by Type
11.5.2.5.2 Nigeria Multiple Myeloma Market by Disease Type
11.5.2.5.3 Nigeria Multiple Myeloma Market by End User
11.5.2.6 South Africa
11.5.2.6.1 South Africa Multiple Myeloma Market by Type
11.5.2.6.2 South Africa Multiple Myeloma Market by Disease Type
11.5.2.6.3 South Africa Multiple Myeloma Market by End User
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Multiple Myeloma Market by Type
11.5.2.7.2 Rest of Africa Multiple Myeloma Market by Disease Type
11.5.2.7.3 Rest of Africa Multiple Myeloma Market by End User
11.6 Latin America
11.6.1 Latin America Multiple Myeloma Market by Country
11.6.2 Latin America Multiple Myeloma Market by Type
11.6.3 Latin America Multiple Myeloma Market by Disease Type
11.6.4 Latin America Multiple Myeloma Market by End User
11.6.5 Brazil
11.6.5.1 Brazil America Multiple Myeloma Market by Type
11.6.5.2 Brazil America Multiple Myeloma Market by Disease Type
11.6.5.3 Brazil America Multiple Myeloma Market by End User
11.6.6 Argentina
11.6.6.1 Argentina America Multiple Myeloma Market by Type
11.6.6.2 Argentina America Multiple Myeloma Market by Disease Type
11.6.6.3 Argentina America Multiple Myeloma Market by End User
11.6.7 Colombia
11.6.7.1 Colombia America Multiple Myeloma Market by Type
11.6.7.2 Colombia America Multiple Myeloma Market by Disease Type
11.6.7.3 Colombia America Multiple Myeloma Market by End User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Multiple Myeloma Market by Type
11.6.8.2 Rest of Latin America Multiple Myeloma Market by Disease Type
11.6.8.3 Rest of Latin America Multiple Myeloma Market by End User

12 Company Profile
12.1 Takeda Pharmaceutical Company Limited
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Teva Pharmaceutical Industries Ltd
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Novartis AG
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Amgen Inc
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Bristol Myers Squibb Company
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Janssen Pharmaceuticals, Inc
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 ONO PHARMACEUTICAL CO., LTD
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 CELGENE CORPORATION
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Genentech, Inc.
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Abbie Inc.
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View

13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions

14. Use Case and Best Practices

15. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone